`U.S. Patent 10,335,462
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`______________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`______________________
`
`MYLAN PHARMACEUTICALS, INC.,
`Petitioner
`
`
`v.
`
`NOVO NORDISK A/S,
`Patent Owner
`______________________
`Case IPR2023-00724
`Patent 10,335,462
`______________________
`
`DECLARATION OF JENNY C. WU IN SUPPORT OF
`PATENT OWNER’S UNOPPOSED MOTION FOR
`PRO HAC VICE ADMISSION
`
`
`1
`
`
`
`
`
`
`
`
`
`
`
`
`Novo Nordisk Exhibit 2533
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00001
`
`
`
`IPR2023-00724
`U.S. Patent 10,335,462
`
`Pursuant to 37 C.F.R. § 1.68, I, Jenny C. Wu, declare as follows:
`
`1.
`
`I am a member in good standing of the New York Bar. I am admitted to
`
`practice before the United States District Court for the Southern District of New
`
`York, the United States District Court for the Eastern District of New York, the
`
`United States District Court for the Eastern District of Michigan, the United States
`
`District Court for the Western District of Wisconsin, and the United States Court
`
`of Appeals for the Federal Circuit. I have personal knowledge of the facts set forth
`
`in this Declaration. All statements herein made of my own knowledge are true and
`
`all statements made on information and belief are believed to be true.
`
`2.
`
`I have never been suspended or disbarred from practice before any court or
`
`administrative body.
`
`3.
`
`I have never had any application for admission to practice before any court
`
`or administrative body ever denied.
`
`4.
`
`I have never had any sanctions or contempt citations imposed against me
`
`by any court or administrative body.
`
`5.
`
`I have read and will comply with the Patent Trial and Appeal Board
`
`Consolidated Trial Practice Guide and the Board’s Rules for Practice for Trials
`
`set forth in part 42 of title 37 of the Code of Federal Regulations.
`
`
`
`2
`
`Novo Nordisk Exhibit 2533
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00002
`
`
`
`IPR2023-00724
`U.S. Patent 10,335,462
`
`6.
`
`I agree to be subject to the USPTO Rules of Professional Conduct set forth
`
`in 37 C.F.R. §§ 11.101 et seq., and to disciplinary jurisdiction under 37 C.F.R.
`
`§ 11.19(a).
`
`7.
`
`In the last three years, I have applied and have been granted to appear
`
`pro hac vice in IPR2021-01398, IPR2021-01430, and IPR2021-01458
`
`proceedings before the United States Patent and Trademark Office.
`
`8.
`
`I have an established familiarity with U.S. Patent No. 10,335,462 (the
`
`“’462 Patent”), the patented technology, and the specific subject matter in this
`
`proceeding. Since April 2023, I have been heavily involved with this
`
`proceeding, including in the analysis of the claim construction and invalidity
`
`issues raised by Mylan. I have substantively participated in the analysis of the
`
`Petition, preparation of the Patent Owner’s Preliminary Response, analysis of
`
`the Institution Decision, and Preparation of Patent Owner’s Response, and am
`
`thus familiar with the filings and various issues raised in this proceeding.
`
`9.
`
`I am an experienced litigation attorney and have been practicing law for
`
`over 10 years. During this time, I have litigated numerous patent infringement
`
`cases at all stages in many different District Courts across the country. I have
`
`been part of multiple trials, Markman hearings, patent summary judgment
`
`proceedings, patent appeals at the United States Court of Appeals for the Federal
`
`
`
`3
`
`Novo Nordisk Exhibit 2533
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00003
`
`
`
`IPR2023-00724
`U.S. Patent 10,335,462
`
`Circuit, and other patent-related hearings and pleadings concerning, inter alia,
`
`patent validity and infringement issues.
`
`10.
`
`I have been warned that willful false statements and the like are punishable
`
`by fine or imprisonment, or both (18 U.S.C. 1001) and may jeopardize the validity
`
`of the patent at issue in this proceeding.
`
`
`
`I declare under penalty of perjury that the foregoing is true and correct.
`
`Dated: March 6, 2024
`
`/Jenny Wu /
`Jenny C. Wu
`
`
`
`
`
`
`
`4
`
`Novo Nordisk Exhibit 2533
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00004
`
`